Abiraterone

Generic Name
Abiraterone
Brand Names
Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
Drug Type
Small Molecule
Chemical Formula
C24H31NO
CAS Number
154229-19-3
Unique Ingredient Identifier
G819A456D0
Background

Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...

Indication

Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...

Associated Conditions
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Associated Therapies
-
Clinical Trials
Related News

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

First Posted Date
2024-04-25
Last Posted Date
2024-06-07
Lead Sponsor
Ivan de Kouchkovsky, MD
Target Recruit Count
32
Registration Number
NCT06384222
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial

First Posted Date
2024-04-23
Last Posted Date
2024-11-26
Lead Sponsor
Mayo Clinic
Target Recruit Count
120
Registration Number
NCT06378866
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer

First Posted Date
2024-04-17
Last Posted Date
2024-04-24
Lead Sponsor
Mayo Clinic
Target Recruit Count
64
Registration Number
NCT06369610
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

First Posted Date
2024-03-20
Last Posted Date
2024-08-09
Lead Sponsor
University College, London
Target Recruit Count
8000
Registration Number
NCT06320067
Locations
🇬🇧

University College London Hospitals NHS Foundation Trust, London, United Kingdom

🇬🇧

The Royal Marsden Hospital, Sutton, United Kingdom

🇬🇧

Royal Devon University Hospital Trust, Exeter, United Kingdom

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

First Posted Date
2024-01-08
Last Posted Date
2024-01-08
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
10
Registration Number
NCT06193993
Locations
🇸🇬

National University Hospital, Singapore, Singapore

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

First Posted Date
2023-12-15
Last Posted Date
2024-12-18
Lead Sponsor
Mamta Parikh
Target Recruit Count
75
Registration Number
NCT06173362
Locations
🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

First Posted Date
2023-11-18
Last Posted Date
2024-12-09
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1200
Registration Number
NCT06136624
Locations
🇺🇸

Stanford Cancer Center ( Site 0036), Palo Alto, California, United States

🇳🇱

Amsterdam UMC, locatie VUmc ( Site 1156), Amsterdam, Noord-Holland, Netherlands

🇵🇱

Zachodniopomorskie Centrum Onkologii ( Site 1311), Szczecin, Zachodniopomorskie, Poland

and more 242 locations

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

First Posted Date
2023-11-18
Last Posted Date
2024-12-09
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1500
Registration Number
NCT06136650
Locations
🇺🇸

Stanford Cancer Center ( Site 0036), Palo Alto, California, United States

🇸🇬

National University Hospital ( Site 1201), Singapore, Central Singapore, Singapore

🇹🇭

Chulalongkorn University ( Site 1355), Bangkok, Krung Thep Maha Nakhon, Thailand

and more 264 locations

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

First Posted Date
2023-11-07
Last Posted Date
2024-11-27
Lead Sponsor
AstraZeneca
Target Recruit Count
1800
Registration Number
NCT06120491
Locations
🇬🇧

Research Site, Truro, United Kingdom

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

Phase 2
Active, not recruiting
Conditions
Prostate Cancer
Interventions
Drug: Docetaxel
Drug: ADT
Drug: Abiraterone
First Posted Date
2023-09-29
Last Posted Date
2024-05-07
Lead Sponsor
Northwestern University
Target Recruit Count
150
Registration Number
NCT06060587
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy